Trial Profile
Differential kinetic of HCV-RNA negativization in plasma and peripheral blood mononuclear cells (PBMCs) of patients with chronic hepatitis C (CHC) under telaprevir-based triple therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Dec 2015
Price :
$35
*
At a glance
- Drugs Telaprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- 16 Dec 2015 New trial record